Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

News Conference News EAS 2023

Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1

Michael O'Riordan

May 25, 2023

Presentation EuroPCR 2023

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Presenter: Shigeru Saito

May 18, 2023

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

Presentation JIM 2020

Present and future of resorbable magnesium scaffold. An expert review.

Presenter: Stefano Galli

February 13, 2020

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

L.A. McKeown

October 04, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

Presentation TCT 2016

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Fernando Alfonso

November 02, 2016

Presentation TCT 2016

FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Bo Xu

October 31, 2016

Presentation TCT 2016

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Antonio Colombo

October 31, 2016

Presentation TCT 2016

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Ashok Seth

October 31, 2016

Presentation TCT 2016

FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Alexandre Abizaid

October 31, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2016

Shelley Wood

July 28, 2016

Advertisement

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

DES Best for In-Stent Restenosis, but DCBs Also Viable

Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

Good Long-term Results With FANTOM BVS, but More Data Needed

Present and future of resorbable magnesium scaffold. An expert review.

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

TCTMD’s Top 10 Most Popular Stories for July 2016

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content